Atopic Dermatitis

Kara Mudd, PA-C, shares vital insights on atopic dermatitis, rosacea, and contact dermatitis from Maui Derm NP+PA Fall 2025, enhancing clinical practice.

Walter Liszewski, MD, shares innovative and personalized treatment strategies for managing atopic and contact dermatitis at Maui Derm NP+PA Fall 2025.

Discover the latest advancements in pediatric dermatology and atopic dermatitis treatments from Maui Derm NP+PA Fall 2025, featuring expert insights and emerging therapies.

Rebecca Smith, MD, recently led a Dermatology Times Case-Based Roundtable event on complex cases in atopic dermatitis.

Panelists discuss how atopic dermatitis exhibits tremendous heterogeneity in clinical presentation, disease course, symptom variability, environmental triggers, and underlying immunologic and genetic factors that contribute to the challenge of developing one-size-fits-all treatments.

Panelists discuss how despite recent therapeutic advances in atopic dermatitis treatment, significant unmet needs remain including partial responses, lack of long-term stable control, and the need for broader patient response rates and deeper clearance levels.

Berdazimer shows promise for treating MC in pediatric patients, even in those with a history of atopic dermatitis, according to a poster at Maui Derm NP+PA Fall.

Phase 1a results showing STAR-0310’s half-life of up to 68 days, durable cytokine inhibition, and a favorable safety profile will be presented in full at EADV 2025.

Evidence presented at EADV supports upadacitinib’s long-term use in atopic dermatitis and other inflammatory conditions.

At week 16, up to 61% mean EASI reduction was observed in high-dose patients versus 31% in placebo.

Treatment with APG777 led to a significant 71.0% reduction in EASI scores from baseline to week 16, compared to a 33.8% reduction with placebo, according to data presented at EADV 2025.

Galvokamig, a biologic targeting IL-13 and IL-17A/F, demonstrated significant benefits in moderate to severe atopic dermatitis.

Tiffany Mayo, MD, recently moderated a Dermatology Times Case-Based Roundtable event to discuss topical innovation, systemic options, and patient-centered factors when treating atopic dermatitis.

Together with earlier trials presented at EADV, these findings support OX40 receptor inhibition as a promising therapeutic approach for AD.

At EADV 2025, she showcased how OX40 and JAK inhibition offer complementary approaches to long-term disease control.

Nicole Harter, MD, explores ruxolitinib 1.5% cream for pediatric atopic dermatitis, offering a novel, effective treatment option for children aged 2 to 11.

Ruxolitinib cream has become the first topical JAK inhibitor available for pediatric atopic dermatitis (AD) in the US.

Major unmet needs in pediatric AD include rapid itch relief, access, affordability, and better options for sensitive skin.

LEO Pharma unveils promising phase 2b trial results for temtokibart, showcasing significant improvements in atopic dermatitis at EADV Congress 2025.

Presented at EADV Congress 2025, galvokimig showed promising early results in treating moderate to severe atopic dermatitis, targeting multiple inflammatory pathways for effective relief.

Data presented at EADV 2025 on the ROCKET-SHUTTLE trial demonstrate that rocatinlimab, a T-cell rebalancing therapy, significantly improves the signs and symptoms of moderate to severe AD in adults when used with topical therapies.

A new study at EADV 2025 links atopic dermatitis to increased suicidal ideation, highlighting the condition's severe psychological impact.

New guidelines redefine short-term corticosteroid use in patients with AD, urging safer treatment transitions to advanced therapies for better outcomes.

Experts discuss innovative topical therapies for pediatric AD, emphasizing individualized treatment and the importance of managing itch and sleep quality.

Cigna’s removal of restrictions on home phototherapy, following a similar decision by Elevance Health, expands access to more than 66 million Americans.